OncoMatch/Clinical Trials/NCT06305910
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
Is NCT06305910 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Treatment with CD200AR-L for diffuse midline glioma, h3 k27m-mutant.
Treatment: Treatment with CD200AR-L — This is a single center Phase I study of a new adjuvant CD200 activation receptor ligand, CD200AR-L, in combination with imiquimod and GBM6-AD vaccine to treat malignant glioma in children and young adults. The primary objective of this study is to determine the maximum tolerated dose (MTD) of CD200AR-L when given with a fixed dose of GBM6-AD vaccine, imiquimod, and a single dose of radiation for patients with recurrent High Grade Glioma (HGG) or following standard of care therapy radiation therapy for newly diagnosed Newly Diagnosed Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma (DIPG/DMG).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Intrinsic Pontine Glioma
Glioblastoma
Biomarker criteria
Required: H3C2 K27M
documented H3K27M alteration (based on IHC or DNA sequencing performed in a CLIA-certified laboratory)
Demographics
Prior therapy
Must have received: radiation therapy — at diagnosis (for recurrent HGG)
Recurrent HGG must have received standard of care radiation at diagnosis
Lab requirements
Blood counts
absolute neutrophil (segmented and bands) count (anc) ≥1.0 x 10e9/l, platelets ≥75 x 10e9/l; hemoglobin ≥8 g/dl
Kidney function
normal serum creatinine for age or creatinine clearance >60 ml/min/1.73 me2
Liver function
bilirubin ≤1.3 mg/dl and sgpt (alt) ≤2.5 x upper limit of normal (uln) for age
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Minnesota · Minneapolis, Minnesota
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06305910 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received radiation therapy.
Does this trial require H3C2?
Yes, H3C2 K27M is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 25 years or younger and at least 2 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify